New shot could help fight Hard-to-Treat lymphomas
NCT ID NCT06504394
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tests an injectable form of the cancer drug pembrolizumab (Keytruda) in 66 adults whose Hodgkin lymphoma or primary mediastinal B-cell lymphoma has returned or not responded to prior treatment. The main goals are to measure how much drug gets into the body and how many patients see their tumors shrink or disappear. The drug is given as a shot under the skin, and researchers will also monitor safety and how long any response lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara Universitesi Tıp Fakultesi Hastanesi ( Site 0801)
Ankara, 06100, Turkey (Türkiye)
-
Auckland City Hospital ( Site 1001)
Auckland, 1023, New Zealand
-
Biocenter ( Site 0203)
Concepción, Biobio, 4070196, Chile
-
Bradfordhill-Clinical Area ( Site 0202)
Santiago, Region M. de Santiago, 8420383, Chile
-
Centro de Investigacion Clinica de Oaxaca ( Site 0405)
Oaxaca City, 68020, Mexico
-
Churchill Hospital ( Site 0604)
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Clinical Research Alliance ( Site 0101)
Westbury, New York, 11590, United States
-
Clínica Inmunocel ( Site 0201)
Santiago, Region M. de Santiago, 7580206, Chile
-
Comprehensive Cancer Centers of Nevada ( Site 0114)
Las Vegas, Nevada, 89169, United States
-
FALP ( Site 0207)
Santiago, Region M. de Santiago, 7500921, Chile
-
Glan Clwyd Hospital ( Site 0602)
Bodelwyddan, Denbighshire, LL18 5UJ, United Kingdom
-
Hacettepe Universite Hastaneleri ( Site 0802)
Ankara, 06230, Turkey (Türkiye)
-
Health Pharma Professional Research S.A. de C.V: ( Site 0403)
Mexico City, Mexico City, 03100, Mexico
-
Hospital Universitario 12 de Octubre-Hemathology and hemotherapy ( Site 0701)
Madrid, 28041, Spain
-
Hospital Universitario de Salamanca ( Site 0702)
Salamanca, Castille and León, 37007, Spain
-
IC La Serena Research ( Site 0204)
La Serena, Coquimbo Region, 1720430, Chile
-
Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 0703)
L'Hospitalet Del Llobregat, Barcelona, 08908, Spain
-
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0504)
Gliwice, Silesian Voivodeship, 44-102, Poland
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 0501)
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Ondokuz Mayıs Universitesi ( Site 0803)
Samsun, 55270, Turkey (Türkiye)
-
Pratia MCM Krakow ( Site 0503)
Krakow, Lesser Poland Voivodeship, 30-727, Poland
-
Seoul National University Hospital-Oncology ( Site 1101)
Seoul, 03080, South Korea
-
The Christie NHS Foundation Trust ( Site 0603)
Manchester, m20 4bx, United Kingdom
-
Universitaetsklinikum Essen ( Site 1302)
Essen, North Rhine-Westphalia, 45147, Germany
-
University College London Hospital ( Site 0605)
London, London, City of, NW1 2PG, United Kingdom
-
University of Iowa - Waukee ( Site 0111)
Waukee, Iowa, 50263, United States
-
University of Iowa-Holden Comprehensive Cancer Center ( Site 0115)
Iowa City, Iowa, 52242, United States
-
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0502)
Gdansk, Pomeranian Voivodeship, 80-214, Poland
-
Westmead Hospital ( Site 0901)
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.